

## Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drug/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee and also posted on the Division’s web page at <http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf> shortly following each meeting.

MO HealthNet Division’s clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD. All clinical information for consideration should be forwarded to Joshua Moore at [Joshua.S.Moore@dss.mo.gov](mailto:Joshua.S.Moore@dss.mo.gov) or call (573) 751-6961. These submissions should generally follow the AMCP guideline format. Financial evaluations for these therapeutic class reviews are conducted by Conduent State HealthCare, LLC. Companies wishing to discuss opportunities for supplemental rebates should contact Conduent State HealthCare, LLC at (804) 965-8117.

If you have any questions concerning the PDL submission process, or the policy surrounding the process, feel free to contact the pharmacy program at [MHD.ClinicalServices@dss.mo.gov](mailto:MHD.ClinicalServices@dss.mo.gov) or (573) 751-6961. If a public presentation is desired, please contact **Carmen Burton** at [Carmen.M.Burton@dss.mo.gov](mailto:Carmen.M.Burton@dss.mo.gov) or call (573) 751-6961. The Drug PA Committee will convene at **10:00 a.m. on Thursday, September 15, 2022.**

Drug Therapeutic Class Name	
<ul style="list-style-type: none"> <li>• ACE Inhibitors &amp; ACE Inhibitor Diuretic Combination Agents</li> <li>• ACE Inhibitors/CCB Combinations</li> <li>• ADHD, Amphetamines Long Acting</li> <li>• ADHD, Amphetamines Short Acting</li> <li>• ADHD, Methylphenidate Long Acting</li> <li>• ADHD, Methylphenidate Short Acting</li> <li>• ADHD, Non-Stimulants</li> <li>• Alpha-Glucosidase Inhibitors</li> <li>• Amylin Analogs</li> <li>• Antibiotics, GI Oral</li> <li>• Antibiotics, Mupirocin Topical</li> <li>• Antibiotics, Vaginal</li> <li>• Anticoagulants, Oral &amp; SQ</li> <li>• Anticonvulsants, Rescue Agents</li> <li>• Antihyperuricemic Agents</li> <li>• Antiplatelets</li> <li>• ARB &amp; ARB/Diuretic Combinations</li> <li>• ARB/CCB Combination Agents</li> <li>• Benign Prostatic Hyperplasia Agents</li> </ul>	<ul style="list-style-type: none"> <li>• Beta Blockers &amp; Beta Blockers/Diuretic Combinations</li> <li>• Biguanides and Combination Agents</li> <li>• Bile Salt Agents</li> <li>• Bone Ossification Agents</li> <li>• CCB Agents, Dihydropyridines</li> <li>• CCB Agents, Non-Dihydropyridines</li> <li>• Cephalosporins</li> <li>• Colony Stimulating Factors</li> <li>• Cryopyrin-Associated Periodic Syndrome Agents</li> <li>• Direct Renin Inhibitors &amp; Combinations</li> <li>• DPP-IV Inhibitors and Combination Agents</li> <li>• Dry Eye Disease Agents</li> <li>• Electrolyte Depleters, Phosphate Lowering</li> <li>• Electrolyte Depleters, Potassium Lowering</li> <li>• Erythropoiesis Stimulating Agents</li> <li>• Fluoroquinolones, Oral</li> <li>• GI Antibiotics, Oral</li> <li>• GLP-1 Receptor Agonists</li> </ul>

<ul style="list-style-type: none"> <li>• Growth Hormone Agents, Somatropin</li> <li>• Growth Hormone and Growth Hormone Releasing Factors, Select Agents</li> <li>• Homozygous Familial Hypercholesterolemia (HoFH) Agents</li> <li>• Insulin, Long Acting</li> <li>• Insulin, Mixed</li> <li>• Insulin, Non-Analogs</li> <li>• Insulin, Rapid Acting</li> <li>• LHRH, GHRH Antagonists, Injectable</li> <li>• LHRH, GHRH Antagonists, Oral</li> <li>• Macrolides</li> <li>• Meglitinides</li> <li>• Methotrexate Agents</li> <li>• Multiple Sclerosis Agents, Injectable</li> <li>• Multiple Sclerosis Agents, Oral</li> <li>• Niacin Derivatives</li> <li>• PAH, Endothelin Receptor Antagonists (ETRA) Oral</li> <li>• PAH, Phosphodiesterase-5 (PDE5) Inhibitors &amp; Soluble Guanylate Cyclase (SGC) Oral</li> <li>• PAH, Prostacyclins Inhaled</li> <li>• PAH, Prostacyclins Injectable</li> <li>• PAH, Prostacyclins Oral</li> <li>• Penicillins</li> <li>• Pregnancy Maintaining Agents, Hormonal</li> <li>• Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Binders</li> </ul>	<ul style="list-style-type: none"> <li>• Proton Pump Inhibitors</li> <li>• SGLT2 Inhibitors and Combination Agents</li> <li>• Spinal Muscular Atrophy Agents</li> <li>• Statins (HMG Co-A Reductase Inhibitors) &amp; Combination Agents</li> <li>• Sulfonylureas, Second Generation</li> <li>• Sympatholytic Agents</li> <li>• Targeted Immune Modulators, IL-17A Antibody/IL-17 Receptor Antagonists</li> <li>• Targeted Immune Modulators, IL-23 Inhibitors and IL-23/IL-12 Inhibitors</li> <li>• Targeted Immune Modulators, IL-6 Receptor Inhibitors</li> <li>• Targeted Immune Modulators, JAK Inhibitors</li> <li>• Targeted Immune Modulators, Miscellaneous Allergy- and Asthma-Related Monoclonal Antibodies</li> <li>• Targeted Immune Modulators, Select Agents</li> <li>• Targeted Immune Modulators, TNF Inhibitors</li> <li>• Tetracyclines</li> <li>• Thiazolidinediones and Combination Agents</li> <li>• Thrombocytopenia Agents</li> <li>• Triglyceride Lowering Agents</li> <li>• Urinary Tract Antispasmodics</li> </ul>
--	---